534 related articles for article (PubMed ID: 25062874)
1. Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: a prospective, randomized trial.
Park JY; Jeon TJ; Hwang MW; Sinn DH; Oh TH; Shin WC; Choi WC
Pancreatology; 2014; 14(4):263-7. PubMed ID: 25062874
[TBL] [Abstract][Full Text] [Related]
2. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial.
Ueki T; Otani K; Kawamoto K; Shimizu A; Fujimura N; Sakaguchi S; Matsui T
J Gastroenterol; 2007 Feb; 42(2):161-7. PubMed ID: 17351806
[TBL] [Abstract][Full Text] [Related]
3. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial.
Yoo JW; Ryu JK; Lee SH; Woo SM; Park JK; Yoon WJ; Lee JK; Lee KH; Hwang JH; Kim YT; Yoon YB
Pancreas; 2008 Nov; 37(4):366-70. PubMed ID: 18953247
[TBL] [Abstract][Full Text] [Related]
4. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study.
Fujishiro H; Adachi K; Imaoka T; Hashimoto T; Kohge N; Moriyama N; Suetsugu H; Kawashima K; Komazawa Y; Ishimura N; Ishihara S; Amano Y; Kinoshita Y
J Gastroenterol Hepatol; 2006 Jun; 21(6):1065-9. PubMed ID: 16724996
[TBL] [Abstract][Full Text] [Related]
5. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?
Park KT; Kang DH; Choi CW; Cho M; Park SB; Kim HW; Kim DU; Chung CW; Yoon KT
Pancreas; 2011 Nov; 40(8):1215-9. PubMed ID: 21775918
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial for efficacy of nafamostat mesilate in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Ohuchida J; Chijiiwa K; Imamura N; Nagano M; Hiyoshi M
Pancreas; 2015 Apr; 44(3):415-21. PubMed ID: 25479585
[TBL] [Abstract][Full Text] [Related]
7. Preventive effect of ulinastatin and gabexate mesylate on post-endoscopic retrograde cholangiopancreatography pancreatitis.
Zhang ZF; Yang N; Zhao G; Zhu L; Zhu Y; Wang LX
Chin Med J (Engl); 2010 Sep; 123(18):2600-6. PubMed ID: 21034635
[TBL] [Abstract][Full Text] [Related]
8. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis.
Choi CW; Kang DH; Kim GH; Eum JS; Lee SM; Song GA; Kim DU; Kim ID; Cho M
Gastrointest Endosc; 2009 Apr; 69(4):e11-8. PubMed ID: 19327467
[TBL] [Abstract][Full Text] [Related]
9. Nafamostat Mesylate is Not Effective in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis.
Matsumoto T; Okuwaki K; Imaizumi H; Kida M; Iwai T; Yamauchi H; Kaneko T; Hasegawa R; Masutani H; Tadehara M; Adachi K; Watanabe M; Kurosu T; Tamaki A; Kikuchi H; Ohno T; Koizumi W
Dig Dis Sci; 2021 Dec; 66(12):4475-4484. PubMed ID: 33495919
[TBL] [Abstract][Full Text] [Related]
10. Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: the Emperor's New Clothes or Aladdin's Magic Lamp?
Chen S; Shi H; Zou X; Luo H
Pancreas; 2010 Nov; 39(8):1231-7. PubMed ID: 20531245
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis.
Yuhara H; Ogawa M; Kawaguchi Y; Igarashi M; Shimosegawa T; Mine T
J Gastroenterol; 2014 Mar; 49(3):388-99. PubMed ID: 23720090
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Comparative Study of 24- and 6-Hour Infusion of Nafamostat Mesilate for the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective Randomized Comparison Trial.
Kim SJ; Kang DH; Kim HW; Choi CW; Park SB; Song BJ; Nam HS
Pancreas; 2016 Sep; 45(8):1179-83. PubMed ID: 27253231
[TBL] [Abstract][Full Text] [Related]
13. Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials.
Yu G; Li S; Wan R; Wang X; Hu G
Pancreas; 2015 May; 44(4):561-9. PubMed ID: 25822153
[TBL] [Abstract][Full Text] [Related]
14. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials.
Xie Y; Cheng Z; Deng C; Deng M; Zhang H
Medicine (Baltimore); 2023 Oct; 102(41):e35174. PubMed ID: 37832051
[TBL] [Abstract][Full Text] [Related]
15. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial.
Tsujino T; Komatsu Y; Isayama H; Hirano K; Sasahira N; Yamamoto N; Toda N; Ito Y; Nakai Y; Tada M; Matsumura M; Yoshida H; Kawabe T; Shiratori Y; Omata M
Clin Gastroenterol Hepatol; 2005 Apr; 3(4):376-83. PubMed ID: 15822043
[TBL] [Abstract][Full Text] [Related]
16. [Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?].
Kwon YH; Kim JY; Lee SJ; Jang SY; Park HW; Yang HM; Jung MK; Jeon SW; Cho CM; Tak WY; Kweon YO; Kim SK
Korean J Gastroenterol; 2012 Mar; 59(3):232-8. PubMed ID: 22460572
[TBL] [Abstract][Full Text] [Related]
17. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial.
Yoo KS; Huh KR; Kim YJ; Kim KO; Park CH; Hahn T; Park SH; Kim JH; Park CK; Kwon YJ; Lehman GA
Pancreas; 2011 Mar; 40(2):181-6. PubMed ID: 21206331
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic stents for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis should be inserted up to the pancreatic body or tail.
Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Watanabe K; Nakamura J; Kikuchi H; Waragai Y; Takasumi M; Hikichi T; Ohira H
World J Gastroenterol; 2018 Jun; 24(22):2392-2399. PubMed ID: 29904246
[TBL] [Abstract][Full Text] [Related]
19. The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.
Tsujino T; Isayama H; Nakai Y; Ito Y; Togawa O; Toda N; Arizumi T; Kogure H; Yamamoto K; Mizuno S; Yashima Y; Yagioka H; Sasaki T; Matsubara S; Yamamoto N; Hirano K; Sasahira N; Tada M; Koike K
J Gastroenterol; 2013 Aug; 48(8):982-8. PubMed ID: 23090004
[TBL] [Abstract][Full Text] [Related]
20. Value of Raw Rhubarb Solution in the Precaution of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Patients with High-Risk Factors: A Predictive Random Compared Research in One Center.
Wang C; Li Q; Ye P; Zeng S; Li GH; Chen YX; Zhou XJ; Lv NH
Dig Dis Sci; 2017 Apr; 62(4):1043-1050. PubMed ID: 28194668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
